The 50th Annual Meeting of the American Society of Pharmacognosy

美国生药学会第50届年会

基本信息

  • 批准号:
    7675149
  • 负责人:
  • 金额:
    $ 1.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pharmacognosy has played a pivotal role in the discovery of new medicines for the treatment of the many forms of cancer and a wide variety of other human diseases. Among the important natural products which are in use in the clinic or which are investigational drugs are taxol, etoposide, topotecan/irinotecan, the halichondrin analog E7389, dolastatin derivatives, the anthracyclines and the epothilones, to mention a few. Natural products research continues to be an exciting and promising avenue for the discovery of new therapies and is a very active field worldwide. For 50 years, the American Society of Pharmacognosy (ASP) has been one of the premier scientific societies dedicated to all aspects of natural products research. The ASP Annual Meetings are an outstanding venue for presentation of the most cutting-edge discoveries by the leading researchers in the field. The 2009 ASP Annual Meeting, in celebration of our half-century of existence, is planned to be held in Hawaii - this location will attract many colleagues from Pacific Rim countries, where research and development in pharmacognosy is very active. The meeting attendance is expected to be approximately 750 (about 50% more than a typical ASP meeting), including ~300 students and postdocs. Ten world-class speakers will be invited to speak on their most current results on topics which include plant and marine natural products, microbial genomics and ethnobotany. In addition, contributed oral presentations will allow up to 60 other colleagues to present current work on a broad range of topics, including Antitumor Natural Products/Cancer Chemoprevention, Modern Analytical Techniques, Botanicals/Dietary Supplements/Phytomedicines, Diabetes, Digestive and Kidney Diseases (Session in honor of John Daly), Marine Natural Products, and Infectious and Tropical diseases. Approximately 500 contributed posters will provide a strong depth of coverage of additional topics. Students and postdocs have ample opportunity to present their work as contributed papers in ASP meetings. The organizing committee will make every attempt to attract women and underrepresented minorities to our meeting, and to participate in the organization process. The meeting venue, the Sheraton Waikiki, is in ADA compliance, and any attendees requesting special needs will be accommodated. The overarching goal of the meeting will be to highlight the major advances in the field of natural products chemistry and contributions to human health, as well as to look towards the future role of pharmacognosy to continue to find new cures and therapies. This is consistent with the mission of the NIH, and makes this meeting highly relevant to several Institutes. Public Health Relevance: This meeting will bring together scientists involved in natural product research and drug discovery targeting a broad selection of therapeutic areas. It will advance NIH's human health goals through the exchange of scientific information and the fostering of collaborations in drug discovery.
描述(由申请人提供):生药学在发现治疗多种癌症和各种其他人类疾病的新药方面发挥了关键作用。在临床使用的或作为研究药物的重要天然产物中,仅举几例,有紫杉醇、依托泊苷、拓扑替康/伊立替康、软海绵素类似物E7389、多拉司他汀衍生物、蒽环类和埃博霉素。天然产物研究仍然是发现新疗法的一个令人兴奋和有前途的途径,并且在世界范围内是一个非常活跃的领域。50年来,美国生药学学会(ASP)一直是致力于天然产物研究各个方面的主要科学学会之一。ASP年会是该领域领先研究人员展示最前沿发现的绝佳场所。2009年ASP年会,庆祝我们半个世纪的存在,计划在夏威夷举行-这个位置将吸引许多来自太平洋沿岸国家的同事,那里的生药学研究和开发非常活跃。会议出席人数预计约为750人(比典型的ASP会议多约50%),其中包括约300名学生和博士后。十位世界级的演讲者将被邀请就他们最新的研究成果发表演讲,主题包括植物和海洋天然产品,微生物基因组学和民族植物学。此外,贡献的口头报告将允许多达60名其他同事介绍广泛主题的当前工作,包括抗肿瘤天然产品/癌症化学预防,现代分析技术,植物药/膳食补充剂/植物药,糖尿病,消化和肾脏疾病(John Daly的荣誉会议),海洋天然产品以及传染病和热带疾病。大约500张投稿海报将对其他主题进行深入报道。学生和博士后有足够的机会在ASP会议上以贡献论文的形式展示他们的工作。组委会将尽一切努力吸引妇女和代表性不足的少数民族参加我们的会议,并参与组织过程。会议地点Sheraton Waikiki符合ADA标准,任何有特殊需求的与会者都将得到满足。会议的总体目标是突出天然产物化学领域的重大进展和对人类健康的贡献,并展望生药学未来的作用,继续寻找新的治疗方法和疗法。这与国家卫生研究院的使命是一致的,并使这次会议与几个研究所高度相关。 公共卫生相关性:这次会议将汇集参与天然产物研究和药物发现的科学家,针对广泛的治疗领域。它将通过科学信息的交流和促进药物发现方面的合作来推进NIH的人类健康目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BILL J BAKER其他文献

BILL J BAKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BILL J BAKER', 18)}}的其他基金

Induction of antiprotozoal secondary metabolites from endophytic fungi using epigenetic modifiers
使用表观遗传修饰剂从内生真菌中诱导抗原虫次级代谢产物
  • 批准号:
    10170264
  • 财政年份:
    2020
  • 资助金额:
    $ 1.95万
  • 项目类别:
Natural Product Derived Inhibitors of ESKAPE Pathogens
ESKAPE 病原体天然产物抑制剂
  • 批准号:
    10212513
  • 财政年份:
    2020
  • 资助金额:
    $ 1.95万
  • 项目类别:
Induction of antiprotozoal secondary metabolites from endophytic fungi using epigenetic modifiers
使用表观遗传修饰剂从内生真菌中诱导抗原虫次级代谢产物
  • 批准号:
    10043368
  • 财政年份:
    2020
  • 资助金额:
    $ 1.95万
  • 项目类别:
Bioprospecting antibiotics in the fungal secondary metabolome
真菌次级代谢组中抗生素的生物勘探
  • 批准号:
    8660621
  • 财政年份:
    2013
  • 资助金额:
    $ 1.95万
  • 项目类别:
Bioprospecting antibiotics in the fungal secondary metabolome
真菌次级代谢组中抗生素的生物勘探
  • 批准号:
    8582783
  • 财政年份:
    2013
  • 资助金额:
    $ 1.95万
  • 项目类别:
Natural Product Treatments for Leishmaniasis
治疗利什曼病的天然产品
  • 批准号:
    8721327
  • 财政年份:
    2013
  • 资助金额:
    $ 1.95万
  • 项目类别:
Natural Product Treatments for Leishmaniasis
治疗利什曼病的天然产品
  • 批准号:
    8430736
  • 财政年份:
    2013
  • 资助金额:
    $ 1.95万
  • 项目类别:
The 50th Annual Meeting of the American Society of Pharmacognosy
美国生药学会第50届年会
  • 批准号:
    7849653
  • 财政年份:
    2009
  • 资助金额:
    $ 1.95万
  • 项目类别:
BIOSYNTHETIC STUDIES OF BIOACTIVE ASCIDIAN ALKALOIDS
生物活性海鞘生物碱的生物合成研究
  • 批准号:
    2189826
  • 财政年份:
    1994
  • 资助金额:
    $ 1.95万
  • 项目类别:
BIOSYNTHETIC STUDIES OF EUDISTOMINS C E K AND L
EUDISTOMINS C E K 和 L 的生物合成研究
  • 批准号:
    2066247
  • 财政年份:
    1991
  • 资助金额:
    $ 1.95万
  • 项目类别:

相似海外基金

RUI: BIOPOLYMER - BIObricks POLYketide Metabolic EngineeRing platform for unraveling the biosynthesis of higher anthracyclines
RUI:BIOPOLYMER - BIObricks 聚酮化合物代谢工程平台,用于揭示高级蒽环类药物的生物合成
  • 批准号:
    2321976
  • 财政年份:
    2024
  • 资助金额:
    $ 1.95万
  • 项目类别:
    Standard Grant
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
  • 批准号:
    10378678
  • 财政年份:
    2021
  • 资助金额:
    $ 1.95万
  • 项目类别:
Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines
用纳米颗粒封装的蒽环类药物减轻长期心脏毒性
  • 批准号:
    10195941
  • 财政年份:
    2021
  • 资助金额:
    $ 1.95万
  • 项目类别:
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
儿科肿瘤学中蒽环类药物和顺铂多基因风险预测模型的验证和实施
  • 批准号:
    429174
  • 财政年份:
    2019
  • 资助金额:
    $ 1.95万
  • 项目类别:
    Studentship Programs
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
  • 批准号:
    9351286
  • 财政年份:
    2016
  • 资助金额:
    $ 1.95万
  • 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
  • 批准号:
    9176736
  • 财政年份:
    2016
  • 资助金额:
    $ 1.95万
  • 项目类别:
Linking defects in the uptake transporter OCT1 with cancer patients resistance towards anthracyclines
将摄取转运蛋白 OCT1 的缺陷与癌症患者对蒽环类药物的耐药性联系起来
  • 批准号:
    357190
  • 财政年份:
    2016
  • 资助金额:
    $ 1.95万
  • 项目类别:
    Operating Grants
Anthracyclines disrupt Ca2+ signalling in cardiomyocytes: a contribution to cardiac toxicity
蒽环类药物破坏心肌细胞中的 Ca2 信号传导:导致心脏毒性
  • 批准号:
    nhmrc : 1021342
  • 财政年份:
    2012
  • 资助金额:
    $ 1.95万
  • 项目类别:
    Project Grants
Examination of the Molecular Pharmacology of Anthracyclines Induced via their Interaction with Iron
通过与铁相互作用诱导的蒽环类药物的分子药理学研究
  • 批准号:
    nhmrc : 457310
  • 财政年份:
    2007
  • 资助金额:
    $ 1.95万
  • 项目类别:
    NHMRC Project Grants
Chemical Glycobiology on Anthracyclines
蒽环类药物的化学糖生物学
  • 批准号:
    7442243
  • 财政年份:
    2006
  • 资助金额:
    $ 1.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了